Search results
Results From The WOW.Com Content Network
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
More recent, third-generation DNA sequencers such as PacBio SMRT and Oxford Nanopore offer the possibility of sequencing long molecules, compared to short-read technologies such as Illumina SBS or MGI Tech's DNBSEQ.
Sequencing technologies with a different approach than second-generation platforms were first described as "third-generation" in 2008–2009. [4]There are several companies currently at the heart of third generation sequencing technology development, namely, Pacific Biosciences, Oxford Nanopore Technology, Quantapore (CA-USA), and Stratos (WA-USA).
For premium support please call: 800-290-4726 more ways to reach us
PacBio/Oxford Nanopore reads [16] 2016 / 2018 OS link: MaSuRCA Any size, haploid/diploid genomes Illumina and PacBio/Oxford Nanopore data, legacy 454 and Sanger data [17] 2011 / 2018 OS link: Newbler: genomes, ESTs 454, Sanger 454 Life Sciences: 2004/2012 C link: Phrap: genomes Sanger, 454, Solexa Green, P. 1994 / 2008 C / NC-A link: Plass ...
In November 2018, Illumina proposed the acquisition of Pacific Biosciences for $8.00 per share or around $1.2 billion in total. [30] [31] In December 2019, the Federal Trade Commission (FTC) sued to block the acquisition. [32] The proposed deal was abandoned on January 2, 2020, with Illumina paying Pacific a $98 million termination fee. [33]
The workflow of a typical hybrid genome assembly experiment using second- and third-generation sequencing technologies. Figure adapted from Wang et al., 2012 [14]. One hybrid approach to genome assembly involves supplementing short, accurate second-generation sequencing data (i.e. from IonTorrent, Illumina or Roche 454) with long less accurate third-generation sequencing data (i.e. from PacBio ...
The company's first scientific instrument, called the PacBio RS, was released to a limited set of customers in late 2010., with full commercial release in early 2011. [17] [8] Sequencing provider GATC Biotech was selected by Pacific Biosciences as its first European service provider in late 2010. [18]